Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Fluidigm Corp (FLDM) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011720
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Fluidigm Corp (Fluidigm) formerly known as Mycometrix Corporation, is a biotechnology company which manufactures life-science tools and creates technologies based on microfluidics and mass cytometry. The company’s products systems include biomark HD system, access array system, C1 system, callisto system, EP1 system, polaris system, juno system, and helios. It also provides custom assays such as SNP type assays, maxplar antibodies, delta gene assays and access array assays. Fluidigm offers software, which include fluidigm cytobank analysis, singular analysis toolset, SNP genotyping analysis, real-time PCR analysis, and digital PCR analysis. The company’s C1 system supports mRNA sequencing, DNA sequencing, miRNA analysis and additional applications through the C1 open app IFC. It has operations in France, Canada, Singapore, China, Japan, Australia, the UK and Germany. Fluidigm is headquartered in South San Francisco, California, the US.

Fluidigm Corp (FLDM) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fluidigm Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Fluidigm Corp, Medical Equipment, Deal Details 11
Partnerships 11
Fluidigm Enters into Licensing Agreement with Baylor Genetics Labs 11
Fluidigm Amends Licensing Agreement with Caliper Life Sciences 12
Fluidigm and Ascendas Genomics Enter into Partnership 13
Fluidigm Enters into Distribution Agreement with GenomOncology 14
OpGen Enters into Co-Development Agreement with Fluidigm 15
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 16
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 18
Equity Offering 19
Fluidigm Raises USD30 Million in Public Offering of Shares 19
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 20
Fluidigm Completes Underwriters Over-Allotment Of US$86 Million 22
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 24
Debt Offering 26
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 26
Acquisition 28
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 28
Fluidigm Corp – Key Competitors 30
Fluidigm Corp – Key Employees 31
Fluidigm Corp – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
Aug 04, 2016: Fluidigm Introduces New High-Throughput Targeted NGS Library Preparation System 33
Jun 09, 2016: Fluidigm Announces New Customer Inspiration Center in Canada for Mass Cytometry 34
Financial Announcements 35
Nov 02, 2017: Fluidigm Announces Third Quarter Financial Results and Operational Progress 35
Aug 03, 2017: Fluidigm Announces Second Quarter Financial Results and Operational Progress 37
May 04, 2017: Fluidigm Announces First Quarter Financial Results 39
Feb 08, 2017: Fluidigm Announces Q4 And Full Year 2016 Financial Results 42
Jan 09, 2017: Fluidigm Announces Preliminary Revenue For The Fourth Quarter And Full Year 44
Nov 03, 2016: Fluidigm Announces Third Quarter Financial Results 45
Oct 12, 2016: Fluidigm Announces Preliminary Third Quarter 2016 Revenue 47
Aug 04, 2016: Fluidigm Announces Q2 2016 Financial Results 48
May 05, 2016: Fluidigm Announces First Quarter Financial Results 50
Feb 04, 2016: Fluidigm Announces Q4-Full Year 2015 Financial Results 52
Jan 12, 2016: Fluidigm Announces Preliminary Full Year and Fourth Quarter 2015 Revenue 53
Corporate Communications 54
Mar 27, 2017: Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors 54
Oct 19, 2016: Fluidigm Names S. Christopher Linthwaite as New Chief Executive Officer 55
Aug 04, 2016: Fluidigm Appoints New President and Chief Operating Officer 56
Product News 57
Oct 24, 2017: Fluidigm Introduces Imaging Mass Cytometry System for Highly Multiplexed Protein Detection in Tissues 57
Oct 18, 2017: Fluidigm to Unveil High-Parameter Tissue Imaging System 58
Dec 21, 2016: Fluidigm Introduces A New Medium-Cell High-Throughput Integrated Fluidic Circuit 59
Nov 10, 2016: Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research 60
Other Significant Developments 61
Nov 09, 2016: Fluidigm and GenomOncology Partner to Provide Automated Oncology NGS Library Preparation With Molecular Interpretation and Reporting 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Fluidigm Corp, Medical Equipment, Key Facts, 2016 2
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Fluidigm Corp, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Fluidigm Corp, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Fluidigm Corp, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Fluidigm Corp, Deals By Market, 2011 to YTD 2017 9
Fluidigm Corp, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Fluidigm Enters into Licensing Agreement with Baylor Genetics Labs 11
Fluidigm Amends Licensing Agreement with Caliper Life Sciences 12
Fluidigm and Ascendas Genomics Enter into Partnership 13
Fluidigm Enters into Distribution Agreement with GenomOncology 14
OpGen Enters into Co-Development Agreement with Fluidigm 15
Fluidigm Enters Into Co-Marketing Agreement With Olink Bioscience For Protein Biomarkers 16
Fluidigm Enters Into Co-Development Agreement With DKMS For High Throughput HLA Typing System 18
Fluidigm Raises USD30 Million in Public Offering of Shares 19
Fluidigm Completes Public Offering Of Common Stock For US$60 Million 20
Fluidigm Completes Underwriters Over-Allotment Of US$86 Million 22
Fluidigm Completes IPO Of Common Stock For US$86.3 Million 24
Fluidigm Completes Public Offering Of Notes Due 2034 For US$201.3 Million 26
Fluidigm Completes Acquisition Of DVS Sciences For US$207.5 Million 28
Fluidigm Corp, Key Competitors 30
Fluidigm Corp, Key Employees 31
Fluidigm Corp, Other Locations 32
Fluidigm Corp, Subsidiaries 32

★海外企業調査レポート[Fluidigm Corp (FLDM)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Dr. Reddy’s Laboratories Limited (DRREDDY):企業のM&A・提携動向(医療機器分野)
    Summary Dr. Reddy's Laboratories Limited (Dr. Reddy's) is a pharmaceutical company. The company manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gast …
  • Tokai Pharmaceuticals Inc (TKAI):企業財務及び戦略的SWOT分析
    Summary Tokai Pharmaceuticals Inc (Tokai Pharma) is a biopharmaceutical company that develops and commercializes therapies for the treatment of prostate cancer and other hormonally-driven diseases. The company’s lead drug candidate, galeterone, an oral small molecule drug candidate which is intended …
  • Typhoon Exploration Inc. (TYP):企業財務及び戦略的SWOT分析
    Summary Typhoon Exploration Inc. (Typhoon Exploration) is an energy company that offers mineral exploration services. The company offers acquisition, exploration and development of gold assets. It provides technology for exploration projects. Typhoon Exploration’s operational areas include Fayolle, …
  • Cal Dive International, Inc. (CDVI)(石油・ガス分野):企業M&A動向
    Summary Cal Dive International, Inc. (CDI) is a marine contractor. The company provides services such as derrick services, pipelay services, pipe burial services, and diving services. It owns a diversified fleet of vessels, which include surface and saturation dive support vessels, and construction …
  • Agnico-Eagle Mines Limited:企業の戦略・SWOT・財務分析
    SummaryAgnico-Eagle Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. …
  • PTT Public Company Limited (formerly Petroleum Authority of Thailand):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' PTT Public Company Limited (for …
  • Aushon BioSystems, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Aushon BioSystems, Inc. Mergers …
  • Runcom Technologies, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Runcom Technologies, Ltd. Merge …
  • Wal-Mart Stores Inc:戦略・SWOT・企業財務分析
    Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Modus Therapeutics Holding AB-製薬・医療分野:企業M&A・提携分析
    Summary Modus Therapeutics Holding AB (Modus), formerly known as Dilaforette Holding AB, is a biotechnology company that focuses on the development of sevuparin, a proprietary polysaccharide drug for the treatment of sickle cell disease (SCD). Modus Therapeutics Holding AB - Pharmaceuticals & Health …
  • Harman International Industries Inc:企業の戦略的SWOT分析
    Harman International Industries Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Power Engineering Consulting Joint Stock Company 1 (TV1):企業の財務及び戦略的SWOT分析
    Summary Power Engineering Consulting Company 1 (PECC1), a subsidiary of Vietnam Electricity is a power company that provides engineering advisory services and constructs electric power and other industrial and civil utility projects. The company offers engineering consultancy services such as prepar …
  • Rizal Commercial Banking Corporation (RCB):企業の財務及び戦略的SWOT分析
    Summary Rizal Commercial Banking Corporation (RCBC) is a financial and commercial banking service provider that offers commercial, corporate and consumer banking, treasury, cash management and remittance products and services. The company offers electronic banking services such as internet banking, …
  • Wayport, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Wayport, Inc. Mergers and Acqui …
  • Sprint Bioscience AB (SPRINT):企業のM&A・提携動向(医療分野)
    Summary Sprint Bioscience AB (Sprint Bioscience) is a pharmaceutical company that discovers and develops cancer and metabolism drugs. The company’s products comprise cancer metabolism, autophagy and amino acid metabolism. It operates projects which include PIP4K2a, and Vps34, established FBDD projec …
  • Hyundai Heavy Industries Co., Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Hyundai Heavy Industries Co., L …
  • GI Dynamics Inc (GID)-製薬・医療分野:企業M&A・提携分析
    Summary GI Dynamics Inc (GI Dynamics) is a medical device company that develops and commercializes endoscopy instruments. The company’s product includes EndoBarrier, an endoscopically delivered device therapy that is designed to mimic the mechanisms of metabolic surgery- without altering the anatomy …
  • Asbury Automotive Group, Inc.:企業の戦略・SWOT・財務分析
    SummaryAsbury Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the compan …
  • ICON plc:企業のM&A・提携・投資分析
    ICON plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ICON plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Faes Farma SA (FAE):企業財務及び戦略的SWOT分析
    Faes Farma SA (FAE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆